In this industry-sponsored webinar, speakers discuss updated IPF/PPF guidelines, key utility data, and the role of the Envisia Genomic Classifier in ILD diagnosis and prognosis. New data is presented that demonstrates how the Envisia Classifier can predict clinical progression in fibrotic interstitial lung disease.
---
Sponsored by Veracyte. All opinions expressed and information provided as part of this program are those of the presenters only. The content of this program has not been reviewed by CHEST, and CHEST does not endorse or take any position regarding the contents, opinions, or information associated with this program.
Copyright for this content is held by the American College of Chest Physicians. Permission to redistribute is required.
